Trump Announces New US Generic Drug Tariff: The US administration has taken a big and tough political step in the global pharmaceutical market. Under this, a new tariff structure on bulk import of foreign generic medicines has been officially announced. The main objective of this new policy is to significantly promote the domestic production of medicines in America. Its main goal is to completely eliminate America’s dependence on cheap generic medicines coming from big countries like India and China.
US President Donald Trump has given complete information about his new plan on Truth Social on Tuesday. He said that the new rule will be applicable on all foreign generic medicines imported into America from August 1, 2026. For the initial two years, 0 percent tariff will be imposed on these imported generic medicines, which will not have any immediate impact. After this, the tariff rate will be increased to 100 percent for one year and then to 200 percent immediately after that.
Important steps of Trump’s new plan
This new tariff plan will be fully implemented mainly in three different phases. Under the first phase, there will be no new duties on generic drugs imported into the US for the next two years. This two-year extension has been given so that there is no immediate shortage of life-saving medicines in the American market. With this, domestic pharmaceutical companies can easily get full time to establish their new supply chain.
Heavy tariff of 100 and 200 percent
As soon as the initial two-year transition period is completely over, very stringent rules for the second phase will be implemented. In the second phase, a heavy import duty of 100 per cent will be imposed immediately on the import of foreign generic medicines. In the third and final phase, this tariff limit will be increased to 200 percent, which is quite high. This would make importing foreign drugs into the US market extremely expensive and almost impractical.
Main agenda of Made in America
Donald Trump’s main agenda behind this big decision is to strengthen domestic production in America. The Trump administration wants that the medicines consumed by American citizens should be manufactured entirely on American soil. During the Covid pandemic, America realized that excessive dependence on foreign life-saving drugs was a huge risk for them. This decision has been taken to avoid this national security threat and to reduce foreign dependence.
Direct impact on Indian pharma sector
India is called the pharmacy of the world and the US market is the largest source of revenue for Indian pharma companies. About 40 percent of the generic medicines consumed in America are exported there in large quantities from India alone. In the financial year 2024, India had successfully exported huge pharma products worth $8.73 billion to America. A huge export worth 41.05 million dollars was made to America in April 2025 and 47.42 million dollars in February 2026.
Also read: Trump explodes 50% tariff bomb on Canada, sound of trade war creates panic in global market
Major economic challenges of the future
Due to 0 percent tariff for the initial two years, Indian companies will not face any immediate financial shock at all. But after 2 years, when heavy tariffs of 100 and 200 percent will be implemented, Indian medicines will become very expensive. This will clearly put huge pressure on the profit margins of big companies like Sun Pharma and Dr. Reddy’s. To survive in the American market, Indian companies will be forced to set up new local manufacturing plants there.
Comments are closed.